SCHEMBL3750397

SCHEMBL3750397

CC(C)(CO)NC(=O)c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.54
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
ATM Q13315 1/20 0.52
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
CYP1A2 P05177 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
GABRA5 P31644 2/20 0.49
HTT P42858 1/20 0.49
GAA P10253 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25781021 0.86 L3MBTL1 (0.61) POLBKDM4EALDH1A1LMNAMAPT
SCHEMBL26661471 0.84 NPC1 (0.51) POLBKDM4EALDH1A1LMNAMAPT
SCHEMBL10123127 0.84 RAB9A (0.54) POLBALDH1A1LMNAMAPTL3MBTL1
SCHEMBL706443 0.84 HDAC1 (0.58) POLBLMNAMAPTL3MBTL1NPC1
SCHEMBL6023280 0.84 NPC1 (0.54) POLBALDH1A1LMNAMAPTNPC1
SCHEMBL20300387 0.83 NPC1 (0.50) POLBNPC1RAB9AATMCYP1A2
SCHEMBL28625908 0.82 GRN (0.49) POLBNPC1RAB9AATMCNR1
SCHEMBL4240834 0.82 OGG1 (0.53) POLBKDM4EALDH1A1MAPTL3MBTL1
SCHEMBL3757683 0.82 NPC1 (0.52) POLBKDM4EALDH1A1NPC1RAB9A
SCHEMBL11074386 0.82 NPC1 (0.52) POLBKDM4EALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 POLB 2841/4885KDM4E 4057/4885ALDH1A1 315/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 POLB 3428/4885KDM4E 4100/4885ALDH1A1 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.